Tetrahydroindazoles as Interleukin-2 Inducible T-Cell Kinase Inhibitors. Part II. Second-Generation Analogues with Enhanced Potency, Selectivity, and Pharmacodynamic Modulation in Vivo
Jason D. Burch, Zhonghua Pei, Kevin Lau, Daniel Stein(Evotec (Germany)), Moulay Hicham Alaoui Ismaili, Baihua Hu, Yuan Chen(City Of Hope National Medical Center), Paul McEwan(University of Nottingham), Kathy Barrett, Claire Ellebrandt(Evotec (Germany)), Daniel Kordt(Evotec (Germany)), Charles Eigenbrot(Unknown), Jason DeVoss, Xiaofeng Xu(Hangzhou Normal University), Xiaolu Wang(Tsinghua University), Yong Chen(Sichuan Normal University), Yamin Zhang(Zhejiang Lab), Ali A. Zarrin, John J. Barker(Evotec (United Kingdom)), Zhonghua Lin, Richard Goldsmith, Daniel F. Ortwine, Po‐wai Yuen
Cited by 47
Related Papers
Chemical Synthesis of Single Atomic Site Catalysts
|Chemical Reviews|2020|1.4k
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
|Nature Biotechnology|2012|997
<b>Endocytosis and Sorting of ErbB2 and the Site of Action of Cancer Therapeutics Trastuzumab and Geldanamycin</b>
|Molecular Biology of the Cell|2004|489
Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier
|Science Translational Medicine|2013|267
Resolving <i>TYK2</i> locus genotype-to-phenotype differences in autoimmunity
|Science Translational Medicine|2016|264